Morning Comment Sweden-06/09/2026

Research evidence excerpt

Morning Comment Sweden-06/09/2026

Morning Comment Sweden

9 JUN 2026

Today’s research focus S&P 500 intraday

7.480

• VICO - Vicore Pharma - Buy, TP SEK 97: As a general take from KOL,

tolerability remains one of the major challenges across the IPF pipeline. In 7.460

contrast, Vicore’s has so far demonstrated a very differentiated profile

7.440

with no GI side effects, the potential of FVC gains and combinable with

existing and emerging therapies. The company expects a futility analysis 7.420

to be completed by Q4 2026. Given buloxibutid’s outstanding tolerability,

we expect it to be successful and see a much lower risk of early trial 7.400

termination compared to previous failures. LINK 7.380

• XVIVO - XVIVO Perfusion - Buy, TP SEK 320: Transplant volumes in Q2 7.360

show a positive shift in trends. In the US, liver has led on growth for a while 16:00 17:00 18:00 19:00 20:00 21:00

and continues at a similar pace in Q2 at +7% y/y. Heart has, however, now

taken the top spot at +10.1%, followed by lung at +9.3%. This makes the US and Asia indices (at time of publication)

YTD figures look better overall as the year started on the softer side. Lung 2.50%

for example has accelerated from +0.1% in Q1 to +4.4% YTD. A support 2.00%

to Q2, but more importantly for the long-term story, the market is starting 2.00%

to grow again across the other organs. 1.50%

• HMS - HMS Networks - Hold, TP SEK 539: Japan Machine tool orders 1.00% 0.86% 0.80%

for May came in at +36.4% y/y, solid print but slightly below previous

month at +45%. We currently model +16% organic order intake in Q2. 0.50% 0.30% 0.12%

• DIOS - Diös - Buy, TP SEK 79: Diös has signed a lease agreement with 0.00%

Hanzens for ~1,600 sqm in the MVG shopping centre in central Umeå, -0.50% -0.16%